Symbol="NLTX"
AssetType="Common Stock"
Name="Neoleukin Therapeutics"
Description="Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmune disorders using protein design technology. The company is headquartered in Seattle, Washington."
CIK="1404644"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 360 - 1616 EASTLAKE AVE EAST, SEATTLE, WA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="31660200"
EBITDA="-41546000"
PERatio="None"
PEGRatio="None"
BookValue="1.808"
DividendPerShare="0"
DividendYield="0"
EPS="-0.76"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.231"
ReturnOnEquityTTM="-0.436"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.76"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="1.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.185"
EVToRevenue="-"
EVToEBITDA="1.31"
Beta="1.185"
num_52WeekHigh="1.1"
num_52WeekLow="0.375"
num_50DayMovingAverage="0.741"
num_200DayMovingAverage="0.663"
SharesOutstanding="44021400"
DividendDate="None"
ExDividendDate="None"
symbol="NLTX"
open="0.71"
high="0.71"
low="0.66"
price="0.69"
volume="122239.00"
latest_trading_day="2023-08-28"
previous_close="0.72"
change="-0.03"
change_percent="-4.1991%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="35"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="65"
Volume_recent_avg="241506"
Change_recent_avg="0.01"
Delta_recent_avg="0.04"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="0.28"
RSI_change="FALSE"
ADX_change="FALSE"

event="aroon_milestone_negative_30"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="65"
Aroon_momentum_negative="35"
image_negative_thumbnail_id_1="1130"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0163.jpeg"
image_negative_thumbnail_id_2="109"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0067.jpeg"
image_neutral_thumbnail_id_1="553"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0046.jpeg"
image_neutral_thumbnail_id_2="566"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0033.jpeg"
image_positive_thumbnail_id_1="969"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0131.jpeg"
image_positive_thumbnail_id_2="665"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0043.jpeg"
image_professor_thumbnail_id_1="1201"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
image_professor_thumbnail_id_2="1195"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0029.jpeg"
